Cozart RapiScan Oral Fluid Drug Testing System: an evaluation of sensitivity, specificity, and efficiency for XXXX detection compared with ELISA and GC- @entity15 following controlled @entity2072 administration.

@entity29427 @entity2072 @entity91 @entity15 @entity3234
Oral fluid has become a widely accepted alternative matrix for drugs of abuse detection. Immunoassays have been developed for on-site testing of @entity2072 and metabolites in oral fluid. The performance of the Cozart RapiScan Oral Fluid Drug Testing System ( @entity91 ) was evaluated in comparison with Cozart Microplate Enzyme Immunoassay @entity2072 Oral Fluid Kit (COC ELISA) and gas chromatography-mass spectrometry (GC- @entity15 ) at several screening and confirmation cutoffs, including those proposed by SAMHSA and those currently in use in the U.K. Oral fluid samples (n = 1271) were collected prior to and following controlled clinical @entity2072 administration. @entity91 provides a qualitative screen at a preset cutoff of 30 microg/L. Sensitivity, specificity, and efficiency for @entity91 (30 microg/L) as compared with COC ELISA with a cutoff of 30 microg/L were 92.1%, 91.8%, and 92.0%. The comparison of @entity91 (30 microg/L) with the 8-mg/L proposed SAMHSA confirmation cutoffs for @entity2072 and/or @entity3234 exhibited a sensitivity of 82.7%, a specificity of 94.5%, and an efficiency of 87.6%. For this study, an alternative @entity91 cutoff of 20 microg/L was also evaluated. Performance characteristics of @entity91 (20 microg/L) at the proposed SAMHSA confirmation cutoffs were 89.9%, 89.7%, and 89.8%, respectively. At cutoffs in use in the U.K., 30- micro g/L @entity91 screen and 15- microg/L GC- @entity15 cutoffs for @entity2072 , @entity3234 , and/or @entity29427 sensitivity, specificity, and efficiency were 89.4%, 92.2%, and 90.7%, respectively. Cozart RapiScan had performance similar to the COC ELISA assay for the detection of @entity2072 exposure and suitable sensitivity and specificity at the proposed SAMHSA cutoffs.
